Published: 2 June 2022
Publications
Recent approvals: New active ingredients or new indications
Published 2 June 2022
Prescriber Update 43(2): 21
June 2022
For the period 16 January to 15 April 2022.
Recent approvals of medicines with new active ingredients
Trade name (active ingredient) | Dose form and strength(s) | Therapeutic area |
---|---|---|
Ajovy (fremanezumab) | Solution for injection 225 mg/1.5 mL |
Migraine |
Evrysdi (risdiplam) | Powder for oral solution 750 mcg/mL |
Spinal muscular atrophy |
Zejula (niraparib) | Capsule 100 mg |
Epithelial ovarian, fallopian tube, or primary peritoneal cancer |
Nuvaxovid* (COVID-19 vaccine with Matrix-M adjuvant) | Solution for injection 10 mcg/mL |
COVID-19 prevention |
Paxlovid* (nirmatrelvir; ritonavir) | Film-coated tablet 150 mg/100 mg |
COVID-19 treatment |
Lagevrio* (molnupiravir) | Capsule 200 mg |
COVID-19 treatment |
* Provisional approval.
Approved medicines with new indications
Trade Name (active ingredient) | Dose form and strength(s) | New therapeutic area(s) |
---|---|---|
Lenvima (lenvatinib) | Capsule 4 mg 10 mg |
Endometrial carcinoma |
Xolair (omalizumab) | Solution for injection 75 mg 150 mg |
Chronic rhinosinusitis with nasal polyps |
Yervoy (ipilimumab) | Concentrate for injection 50 mg/10 mL 200 mg/40 mL |
Malignant pleural mesothelioma |
Winglore (ipilimumab) | Concentrate for injection 50 mg/10 mL 200 mg/40 mL |
Malignant pleural mesothelioma |
Keytruda (pembrolizumab) | Concentrate for infusion 25 mg/mL (100 mg/4 mL) |
Endometrial carcinoma |
Opdivo (nivolumab) | Concentrate for infusion 40 mg/4 mL 100 mg/10 mL |
Malignant pleural mesothelioma Oesophageal squamous cell carcinoma |
See the Medsafe website for: